Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Media
Case-Based Peer PerspectivesInvestigator Perspectives Medical World NewsPodcastsUrology Medical PerspectivesUTv VideosPeer ExchangeSpecial ReportVirtual Tumor BoardClinical Forum InsightsInsightsMedcastPeers & Perspectives
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Simon P. Kim, MD, MPH

Advertisement

Articles by Simon P. Kim, MD, MPH

Role of LND in patients undergoing radical nephroureterectomy

BySimon P. Kim, MD, MPH
December 1st 2016
Advertisement

Latest Updated Articles

  • Role of LND in patients undergoing radical nephroureterectomy
    Role of LND in patients undergoing radical nephroureterectomy

    Published: December 1st 2016 | Updated:



Advertisement
Advertisement

Trending on Urology Times

1

Novel tool may help predict early PSA response to ARPIs in mHSPC

2

Dosing begins in trial of alpha radioligand therapy for mCRPC

3

Fed Ghali, MD, highlights trial of consolidative local therapy following EV/P

4

RCMIGI trial supports feasibility of reduced margins in image-guided prostate radiotherapy

5

Mark Tyson, MD, highlights ADVANCED-2 trial in BCG-naïve NMIBC

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do not sell my Personnal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us